Browse recruiting and upcoming clinical trials for wild-type ATTR amyloidosis.
Patient-friendly, AI-assisted summaries based on official ClinicalTrials.gov ↗ records. Last updated: Oct 10, 2026
About this listHide
ClinicalTrials.gov is the complete and most up-to-date source. Trials may be missing, and trial information may have changed since our last check. Always verify important information in the official registry.
Who can join AIAdults with cardiac light‑chain (AL) amyloidosis (age 18+), transthyretin (ATTR) cardiac amyloidosis (age 65+), or adults age 65+ without amyloidosis (controls).
What is being studied AIHigh-mechanical-index ultrasound with Definity plus PET and echocardiography to measure heart blood flow and function.
Who can join AIAdults (18+) with transthyretin‑mediated amyloid cardiomyopathy (ATTR‑CM) who meet prior‑study participation or completion requirements.
What is being studied AITests long-term safety and tolerability of monthly eplontersen in ATTR-CM.
Who can join AIAdults with EMG-confirmed carpal tunnel syndrome scheduled for endoscopic carpal tunnel surgery; study compares biopsies for transthyretin amyloidosis detection.
What is being studied AIWhether ligament biopsy during endoscopic surgery agrees with synovial biopsy for transthyretin amyloidosis detection.
Who can join AIAdults 18–100 with suspected cardiac transthyretin (ATTR) amyloidosis and heart failure who meet specific imaging and biomarker criteria.
What is being studied AITests quantitative myocardial uptake of 99mTc bone tracers with CZT SPECT-CT.
Who can join AIPeople with wild-type or hereditary transthyretin (TTR) cardiac amyloidosis (ATTR‑CA) and age‑matched patients with non-amyloid hypertrophic cardiomyopathy.
What is being studied AIMeasures liver function, liver stiffness (FibroScan) and detailed coagulation tests in ATTR-CA and controls.
Who can join AIAdults with transthyretin amyloid cardiomyopathy (ATTR-CM) or adults with heart failure who have recent documentation that excludes ATTR-CM or shows a low probability of it.
What is being studied AICollects retinal fundus and OCT images to develop a machine-learning screen for ATTR-CM.
Who can join AIAdults (≥18) with confirmed transthyretin (ATTR) amyloidosis — including cardiomyopathy or polyneuropathy — who are in the D8450R00003 cohort.
What is being studied AICollects long-term safety and use data for eplontersen users, including liver transplant and severe hepatic impairment.
Who can join AIAdults with hypertrophic‑phenotype cardiomyopathies (including sarcomeric and non‑sarcomeric HCM, Anderson‑Fabry, and amyloid), their first‑degree relatives, and genetic carriers.
What is being studied AICompares CMR myocardial perfusion patterns across different hypertrophic cardiomyopathy phenotypes.
Who can join AIAdults (18+) who are having a clinically indicated endomyocardial biopsy for heart transplant care, cardiomyopathies, myocarditis/pericarditis, cardiac amyloidosis, or cardiac sarcoidosis.
What is being studied AICollects and analyzes extra endomyocardial biopsy samples for molecular and immune profiling.
Who can join AIPeople aged ≥60 with non‑reduced LVEF heart failure or left ventricular hypertrophy (with or without ATTR‑CM), or control subjects without heart failure. The amyloid arm requires confirmed transthyretin (ATTR-CM) amyloidosis with AL amyloidosis ruled out.
What is being studied AICollects heart and liver shear wave velocity (SWV) measurements using an investigational ultrasound device.
Who can join AIPregnant or lactating individuals with an approved indication for eplontersen who were exposed to eplontersen, and infants linked to those exposures.
What is being studied AICollects and describes pregnancy, birth, and infant outcomes after eplontersen exposure.
Who can join AIPeople referred for a cerebral amyloid PET to clarify Alzheimer's disease, including Alzheimer-type dementia, mild cognitive impairment, or cardiac amyloidosis.
What is being studied AIUses cardiac PET/MRI and heart tests to look for amyloid deposits in people undergoing cerebral amyloid PET.
Who can join AIAdults (≥18) with transthyretin (TTR) cardiac amyloidosis diagnosed after an internal-medicine hospitalization at HUS from 01/01/2013 to 31/12/2023.
What is being studied AICounts and describes transthyretin (TTR) cardiac amyloidosis cases seen in internal medicine, 2013–2023.
Who can join AIAdults (18+) with transthyretin amyloid cardiomyopathy (wild-type or hereditary), with echocardiographic assessment of mitral and/or tricuspid regurgitation.
What is being studied AICollects echocardiographic measures of mitral and tricuspid regurgitation and tracks clinical outcomes.
Who can join AIPeople aged 12 and older with cardiomyopathy (including hypertrophic, dilated, arrhythmogenic, cardiac amyloidosis, Fabry, and other forms).
What is being studied AICollects clinical data and analyzes plasma and heart-tissue microRNAs and spatial transcriptomics.
Who can join AIAdults (age ≥18 to 130 years) with a confirmed diagnosis of transthyretin (ATTR) amyloidosis, including ATTR‑CM, ATTRv‑PN, mixed, and hereditary (hATTR) forms.
What is being studied AICollects real-world clinical, treatment, and outcome data including patients treated with eplontersen
Who can join AIPeople with hereditary or wild‑type ATTR (transthyretin) amyloidosis, and pre-symptomatic carriers of a known disease-causing TTR variant.
What is being studied AICollects long-term clinical and safety data on people with ATTR amyloidosis and pre-symptomatic carriers.
Who can join AIAdults aged 65 or older, or aged 50-64 with a family history of ATTR amyloidosis or a known TTR gene variant, who need a pacemaker, CRT or ICD and have at least one possible warning sign of cardiac amyloidosis.
What is being studied AICollects chest wall fat-pad and heart biopsies during device implantation to detect ATTR-CM.
Who can join AIAdults (18+) with suspected or confirmed cardiac amyloidosis who are undergoing diagnostic work‑up or are identified before starting specific therapy.
What is being studied AICollects imaging, exercise testing, spectroscopy and blood markers to track cardiac amyloidosis over time.
Who can join AIPeople with suspected transthyretin (ATTR) cardiac amyloidosis — heart-failure patients or asymptomatic TTR variant carriers — with non-diagnostic nuclear scans and high TAD1.
What is being studied AIPET-CT with evuzamitide to detect transthyretin cardiac amyloid when nuclear scans are inconclusive
Who can join AIPeople who have had a coronary CT angiography (CCTA) — either with a recorded cardiomyopathy diagnosis or without cardiovascular disease.
What is being studied AITests whether AI can detect and classify cardiomyopathies from coronary CT angiography images.
Who can join AIPeople suspected of rare cardiomyopathies (e.g., Danon, Fabry, cardiac amyloidosis, Noonan, cardiac sarcoidosis, glycogen storage disease, idiopathic cardiomyopathy) who had a cardiac MRI.
What is being studied AIAdvanced cardiac magnetic resonance (CMR) biomarkers for diagnosis and risk stratification of rare cardiomyopathies.
Trials that may include wild-type ATTR amyloidosis (27)
ClinicalTrials.gov returned these when we searched for this condition, but we could not confirm from the registry records that they are intended for people with it. Check each trial’s eligibility criteria, and ask the study team if you are unsure.
Who can join AIAdults 18–75 who are asymptomatic carriers of a pathogenic or likely pathogenic TTR gene variant, without evidence of ATTR heart or nerve disease.
What is being studied AITests acoramidis versus placebo to prevent development of ATTR-CM or ATTR-PN.
Who can join AIPeople aged 60+ with chronic axonal length‑dependent polyneuropathy and/or small‑fiber neuropathy of unknown cause; study screens for cardiac amyloidosis.
What is being studied AIScreens people with unexplained polyneuropathy for wild-type TTR cardiac amyloidosis using ECG and echocardiography.
Who can join AIPeople aged ≥65 with heart failure with preserved ejection fraction (diastolic HF), being evaluated for transthyretin (ATTR) amyloidosis.
What is being studied AIUses a 99mTc-pyrophosphate (PYP) heart scan to detect transthyretin cardiac amyloidosis.
Who can join AIAdults (18–99) with systemic light‑chain (AL) amyloidosis (with or without heart involvement), and control groups with multiple myeloma or heart failure without amyloidosis.
What is being studied AIPET and cardiac MRI plus blood and microbiome tests to measure cardiac amyloid, metabolism, and microvascular function
Who can join AIPeople aged 60 or older who had surgery for lumbar spinal stenosis or carpal tunnel syndrome and have Congo red–positive connective tissue.
What is being studied AIUses 124I-evuzamitide PET/CT imaging to detect amyloid in the heart and other tissues.
Who can join AIPeople with severe aortic valve stenosis being evaluated for TAVI (transcatheter aortic valve implantation), some of whom may have suspected cardiac amyloidosis.
What is being studied AICollects imaging (echocardiography, CT, Tc99-SPECT/CT, CMR) to detect cardiac amyloidosis.
Who can join AIClinicians (physicians and allied health staff) who order, perform, or interpret TTEs for adult patients (≥18) with AI‑flagged risk for genetic cardiomyopathy, ischemic heart disease, cardiac amyloidosis, or hypertrophic cardiomyopathy.
What is being studied AITests AI analysis of echocardiograms to detect heart disease and study clinician workflow.
Who can join AIPeople who were age 50 or older when they had spinal decompression surgery within the past 20 years. The study examines tissue from that surgery for amyloid, including transthyretin (TTR) amyloid, and may then evaluate participants for ATTR cardiac amyloidosis. People already known to have TTR amyloidosis, or with confirmed AL or AA amyloidosis, cannot join.
What is being studied AICollects spinal specimens and clinical cardiac tests to identify transthyretin (ATTR) cardiac amyloidosis.
Who can join AIPeople who carry pathogenic TTR gene variants (including V122I), matched non‑carrier controls, and people with symptomatic V122I hATTR-CA.
What is being studied AIUses cardiac MRI and blood biomarkers to detect subclinical transthyretin cardiac amyloidosis.
Who can join AIPeople aged 65–85 with moderate-to-severe degenerative aortic stenosis scheduled for transcatheter aortic valve replacement, including those with transthyretin amyloid cardiomyopathy.
What is being studied AIMeasures prevalence and clinical features of cardiac amyloidosis in people with aortic stenosis.